Pain
Conditions
Brief summary
This is a multicenter, randomized, double-blind, dose finding, parallel controlled with active drug and placebo, phase II clinical trial, and the purpose of the study is to evaluate the efficacy and safety of HR18042 tablets for postoperative analgesia after impacted teeth removal surgery.
Interventions
DRUGHR18042 tablets
Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
DRUGPlacebos
Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Multicenter, randomized, double-blind, dose finding, parallel controlled with active drug and placebo, phase II clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old. 2. Scheduled to remove the impacted tooth. 3. Any NRS score reaches the inclusion criteria within 4 hours after the surgery. 4. Willing to comply with the study procedures and requirements. 5. Willing and able to provide written informed consent for this study.
Exclusion criteria
1. Subjects who have used other drugs that have the analgesic effect. 2. Subjects who have used any drug that affect the efficacy and safety of study drug. 3. Subjects who have infection or other complications on the planned oral surgical site. 4. Subjects with hypertension or hypotension during screening period. 5. Subjects with severe cardiovascular and cerebrovascular diseases. 6. Subjects with severe gastrointestinal disease. 7. Subjects with Respiratory diseases. 8. Subjects with a history of seizure, or drug or alcohol abuse. 9. Subjects with significant abnormal electrocardiogram result. 10. Subjects with significant abnormal laboratory value. 11. Subject who were allergic to the study drug and ingredients. 12. Pregnancy, lactation or having recent pregnant plan. 13. Subjects who participated in other clinical research study 30 days before entering this study. 14. Other conditions unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Sum of Pain Intensity Differences (SPID) using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) within 4 hours after drug administration | 0-4 hours after drug administration |
Secondary
| Measure | Time frame |
|---|---|
| the Differences of Pain Intensity (PID) from each evaluating timepoint to baseline using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) after drug administration | 0-12 hours after drug administration |
| Pain relief degree at each evaluating timepoint using pain relief scale (PAR, ranging from 0-4, the larger the number, the more obvious the pain relief) after drug administration | 0-12 hours after drug administration |
| Sum of pain relief degree using pain relief scale (PAR, ranging from 0-4, the larger the number, the more obvious the pain relief) within 4 hours, 6 hours, 8 hours, 12 hours after drug administration (SPAR) | 0 - 4 hours, 6 hours, 8 hours and 12 hours after drug administration |
| Proportion of subjects who reach a 50% reduction in pain intensity from baseline using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) at each evaluating timepoint | 0-12 hours after drug administration |
| the Sum of Pain Intensity Differences (SPID) using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) within 6 hours, 8 hours and 12 hours after drug administration | 0 - 6 hours, 8 hours and 12 hours after drug administration |
| Time from drug administration to the first use of rescue medication | 0-12 hours after drug administration |
| Proportion of subjects who receive rescue therapy during the treatment period | 0-12 hours after drug administration] |
| Subject's overall satisfaction score of the study medication using subject satisfaction scale (ranging from 0-10, the larger the number, the higher the satisfaction) | 12 hours after drug administration |
| Time from drug administration to the first NRS score≤3 | 0-12 hours after drug administration |
Countries
China
Outcome results
None listed